Tavapadon - Cerevel Therapeutics
Alternative Names: CVL 751; PF 6649751; PF-06649751Latest Information Update: 28 Nov 2025
At a glance
- Originator Pfizer
- Developer Cerevel Therapeutics; Pfizer
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Dopamine D1 receptor agonists; Dopamine D5 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Parkinson's disease
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in USA (PO, Tablet)
- 26 Sep 2025 Preregistration for Parkinson's disease (Early-stage disease, In the elderly, In adults) in USA (PO)
- 26 Sep 2025 Preregistration for Parkinson's disease (In adults, In the elderly, Adjunctive treatment) in USA (PO)